Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
27 07 2021
Historique:
received: 22 01 2020
accepted: 12 07 2021
entrez: 28 7 2021
pubmed: 29 7 2021
medline: 5 8 2021
Statut: epublish

Résumé

Activating mutations in the BRAF-MAPK pathway have been reported in histiocytoses, hematological inflammatory neoplasms characterized by multi-organ dissemination of pro-inflammatory myeloid cells. Here, we generate a humanized mouse model of transplantation of human hematopoietic stem and progenitor cells (HSPCs) expressing the activated form of BRAF (BRAF

Identifiants

pubmed: 34315896
doi: 10.1038/s41467-021-24876-1
pii: 10.1038/s41467-021-24876-1
pmc: PMC8316479
doi:

Substances chimiques

Cyclin-Dependent Kinase Inhibitor p16 0
Tumor Necrosis Factor-alpha 0
Green Fluorescent Proteins 147336-22-9
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4559

Informations de copyright

© 2021. The Author(s).

Références

Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20012-7
pubmed: 22123971
Nature. 2006 Nov 30;444(7119):638-42
pubmed: 17136094
Nat Rev Cancer. 2019 Aug;19(8):439-453
pubmed: 31235879
Oncotarget. 2016 Mar 15;7(11):11945-58
pubmed: 26943583
Cytometry A. 2017 Oct;91(10):952-965
pubmed: 28609016
Blood. 2012 Sep 13;120(11):2203-13
pubmed: 22855602
J Clin Oncol. 2012 Oct 1;30(28):e286-90
pubmed: 22869874
Nat Rev Cancer. 2014 Aug;14(8):547-58
pubmed: 25030953
Nat Rev Drug Discov. 2017 Oct;16(10):718-735
pubmed: 28729727
Cell. 2014 Sep 11;158(6):1444
pubmed: 28915370
Science. 2013 Aug 23;341(6148):1233158
pubmed: 23845948
Front Immunol. 2014 Jun 13;5:281
pubmed: 24982657
Leuk Lymphoma. 2014 Nov;55(11):2620-6
pubmed: 24471909
N Engl J Med. 2015 Oct 29;373(18):1733-47
pubmed: 26352686
EMBO Mol Med. 2017 Nov;9(11):1558-1573
pubmed: 28835507
Blood. 2017 Jul 13;130(2):167-175
pubmed: 28512190
J Exp Med. 2015 Feb 9;212(2):281
pubmed: 25646268
Nat Cell Biol. 2019 Jan;21(1):94-101
pubmed: 30602768
N Engl J Med. 2018 Aug 30;379(9):856-868
pubmed: 30157397
Biometrics. 1982 Dec;38(4):963-74
pubmed: 7168798
Nature. 2019 Mar;567(7749):521-524
pubmed: 30867592
Ann Rheum Dis. 2020 Feb;79(2):242-253
pubmed: 31780527
Oncotarget. 2014 Sep 30;5(18):7980-1
pubmed: 25478626
Hematol Oncol Clin North Am. 2015 Oct;29(5):825-38
pubmed: 26461145
Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17031-6
pubmed: 19805069
Cell Stem Cell. 2019 Sep 5;25(3):357-372.e7
pubmed: 31230859
Biogerontology. 2004;5(1):1-10
pubmed: 15138376
Front Immunol. 2016 Sep 16;7:364
pubmed: 27695457
Cancer Res. 2005 Dec 15;65(24):11493-500
pubmed: 16357158
Nat Rev Drug Discov. 2019 Jul;18(7):553-566
pubmed: 30967658
Nat Rev Mol Cell Biol. 2021 Feb;22(2):75-95
pubmed: 33328614

Auteurs

Riccardo Biavasco (R)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Emanuele Lettera (E)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.
Human Oncology and Pathogenesis Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, US.

Kety Giannetti (K)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Diego Gilioli (D)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.

Stefano Beretta (S)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
National Research Council, Institute for Biomedical Technologies, Milan, Italy.

Anastasia Conti (A)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Serena Scala (S)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Daniela Cesana (D)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Pierangela Gallina (P)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Margherita Norelli (M)

Innovative Immunotherapies Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Luca Basso-Ricci (L)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Attilio Bondanza (A)

Innovative Immunotherapies Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Giulio Cavalli (G)

Vita-Salute San Raffaele University, Milan, Italy.
Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Maurilio Ponzoni (M)

Vita-Salute San Raffaele University, Milan, Italy.
Pathology and Lymphoid Malignancies Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Lorenzo Dagna (L)

Vita-Salute San Raffaele University, Milan, Italy.
Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Claudio Doglioni (C)

Vita-Salute San Raffaele University, Milan, Italy.
Unit of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Alessandro Aiuti (A)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.

Ivan Merelli (I)

National Research Council, Institute for Biomedical Technologies, Milan, Italy.

Raffaella Di Micco (R)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy. dimicco.raffaella@hsr.it.

Eugenio Montini (E)

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy. montini.eugenio@hsr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH